Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 5/20 | 0.54 |
| ▸ | ESR1 | P03372 | 4/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.49 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 5/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6440199 | 0.97 | ESR2 (0.54) | ESR2ESR1SCN9AGRIA1CACNG8 | |
| SCHEMBL6916575 | 0.97 | ESR2 (0.54) | ESR2ESR1SCN9AGRIA1CACNG8 | |
| SCHEMBL6439085 | 0.94 | ESR2 (0.56) | ESR2ESR1SCN9AGRIA1CACNG8 | |
| SCHEMBL8022188 | 0.84 | USP2 (0.54) | SCN9ACNR2CNR1USP2POLB | |
| SCHEMBL10818327 | 0.82 | SCN9A (0.55) | SCN9AUSP2POLBCYP1A2PDE10A | |
| SCHEMBL6439386 | 0.81 | ESR2 (0.62) | ESR2ESR1SCN9AGRIA1CACNG8 | |
| SCHEMBL13052920 | 0.76 | USP2 (0.52) | SCN9ACNR2CNR1USP2POLB | |
| SCHEMBL7887660 | 0.75 | SCN9A (0.50) | SCN9ACYP1A2PDE10A | |
| SCHEMBL6440718 | 0.73 | ESR2 (0.52) | ESR2ESR1SCN9AGRIA1CACNG8 | |
| SCHEMBL18334017 | 0.72 | MAPK10 (0.46) | SCN9ACNR2CNR1USP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517897-A2 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20040002524-A1 | Benzimidazole compounds and their use as estrogen agonists/antagonists | CHESWORTH RICHARD (US) | 2004-01-01 | — | — | US | disclosed |
| WO-2004000817-A2 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002524-A1 | Benzimidazole compounds and their use as estrogen agonists/antagonists | ESR1, GPER1, ESR2 | ESR2 3/4885ESR1 1/4885SCN9A 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.